Cargando…
Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
Manogepix (MGX) targets the conserved fungal Gwt1 enzyme required for acylation of inositol early in the glycosylphosphatidylinositol biosynthesis pathway. The prodrug fosmanogepix is currently in clinical development for the treatment of invasive fungal infections. We determined that the median fre...
Autores principales: | Kapoor, Mili, Moloney, Molly, Soltow, Quinlyn A., Pillar, Chris M., Shaw, Karen Joy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187586/ https://www.ncbi.nlm.nih.gov/pubmed/31611349 http://dx.doi.org/10.1128/AAC.01387-19 |
Ejemplares similares
-
In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
por: Shaw, Karen Joy, et al.
Publicado: (2018) -
Enhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility
por: Liston, Sean D., et al.
Publicado: (2020) -
APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia
por: Viriyakosol, Suganya, et al.
Publicado: (2019) -
Fungal Cytological Profiling of Candida albicans Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A
por: Sharp, Marc, et al.
Publicado: (2017) -
168. Efficacy of the Novel gwt1 Inhibitor APX2039 in a Rabbit Model of cryptococcus Meningitis
por: Shaw, Karen J, et al.
Publicado: (2020)